Sanofi shares plunge on Acomplia rejection

An FDA expert panel unanimously rejected Sanofi-Aventis' Acomplia, its would-be obesity blockbuster, out of concerns regarding the drug's potential side effects. And analysts are concerned that the fallout from that vote could put a big dent in the pharma company's efforts to market the drug in Europe. Some analysts are anticipating a tougher label for the drug in Europe.

The FDA panel was primarily concerned that Acomplia increased incidents of suicidal behavior and depression among patients. That's likely to play a major role in influencing the agency's final decision on Acomplia. It wasn't a big leap for investors to make. They sent shares of Sanofi down 8 percent on the news.

- see the release on the FDA' s decision
- read the Dow Jones report

Related Articles:
Sanofi shares slide as FDA delays Acomplia-again. Report
Sanofi shares slip on Acomplia delay. Report
Delays forecasted for blockbuster obesity drug. Report

Suggested Articles

Bristol Myers Squibb may have bounced Jounce from its roster of inherited partners, but it’s hanging onto Anokion, a Swiss autoimmune-focused biotech.

The priority review action date sets Bristol Myers up to win approval for the bluebird-partnered anti-BCMA CAR-T therapy in late March.

The unidentified biotechs are drawn from the portfolio of a €150 million life science-focused fund that Index Ventures set up.